

Using Fiasp® in the under 5's: a case study

Elmarie van Wyk

Paediatric Diabetes Dietitian


September 2022

Background

- ✓ Diagnosed @ 18months
- ✓ Levemir & Novorapid
- ✓ Breastfeeding
- ✓ Challenging social background

- ✓ Dexcom G6
- +/- Optimising ratio's
- +/- Optimising diet - GI
- +/- Optimising bolus behaviour
- ✗ Bolus with night time breastfeeding
- ✗ split dose Levemir
- ✗ Pump / HCL (0.5U increments)
- ✓ Fiasp®

	Previous 3 months
TIR %	35.9
>10 mmol/L	59.6
>13.9 mmol/L	36.1
<3 mmol/L	1.8
<3.9 mmol/L	4.5
Hba1C mmol/L	77
CV %	44.3
SD mmol/L	5.3
ave glucose mmol/L	12



Bolus habits

- Anxiety
- Injecting during/after
- Mismatch of carbs and Insulin

- ☐ Selective Eater
- ☐ small appetite
- ☐ Unpredictable eating

Breastfeeding
20:00-02:00

Fiasp ®: Fasting acting Insulin Aspart

Novorapid + 2 additional ingredients

- = speed of absorption (onset is up to 5min earlier)
- = greater early glucose-lowering effects

▪ Indication:


- Pump/MDI needing tight control
- Rapid post-meal BG rises
 - High GI foods / Breakfast spike

▪ Flexible dosing options

- At first bite (0-2min)
- Within 20min during meal if uncertain about meal acceptance

▪ Evidence Fiasp vs Novorapid:


- Improving post-prandial Glycaemia (injecting before/during/post)
- Similar Hba1C
- ?Risk of Hypos





Has it made a difference?

Clinical outcome:

AGP



- HbA1C 77 to 64mmol/L
- QOL consideration
 - ✓ Less anxiety
 - ✓ Mealtimes more enjoyable



Conclude

Fiasp® useful addition in our toolbox especially for our patients on MDI

Thank you

Any Questions?

References:

- Fath, M et al. Pediatric Diabetes. 2017;18:903-910. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.
- Biester, T; Kordonouri O, Danne, T. Therapeutic advances in Endocrinology and Metabolism. 2018 vol 9(5):157-199. Pharmacotherapy of type1 diabetes in children and adolescents: more than insulin?
- European Medicine Agency: assessment report for paediatric studies submitted according to Article 46 of regulation (EC) no 1901/2006. November 2018
- European Medicine Agency: Fiasp: An overview of Fiasp and why it is authorised in the EU, 2019